K2M Group Holdings, Inc. to Participate in the 2018 RBC Capital Markets Global Healthcare Conference
February 12 2018 - 4:05PM
K2M Group Holdings, Inc. (NASDAQ:KTWO) (the "Company" or "K2M"), a
global leader of complex spine and minimally invasive solutions
focused on achieving three-dimensional Total Body Balance™, today
announced its participation in the 2018 RBC Capital Markets Global
Healthcare Conference at the Lotte New York Palace Hotel in New
York, New York. Management will participate in a fireside chat on
Thursday, February 22 at 2:05 p.m. Eastern Time.
A live audio webcast of the presentation will be provided under
the 'Events & Presentations' section of the Company's investor
relations website at http://Investors.K2M.com/. It is recommended
that listeners log on 15 minutes early in order to register and
download any necessary software. An archive of the webcast will be
available for replay following the conference.
About K2M
K2M Group Holdings, Inc. is a global leader of complex spine and
minimally invasive solutions focused on achieving three-dimensional
Total Body Balance. Since its inception, K2M has designed,
developed, and commercialized innovative complex spine and
minimally invasive spine technologies and techniques used by spine
surgeons to treat some of the most complicated spinal pathologies.
K2M has leveraged these core competencies into Balance ACS®, a
platform of products, services, and research to help surgeons
achieve three-dimensional spinal balance across the axial, coronal,
and sagittal planes, with the goal of supporting the full continuum
of care to facilitate quality patient outcomes. The Balance ACS
platform, in combination with the Company's technologies,
techniques and leadership in the 3D-printing of spinal devices,
enable K2M to compete favorably in the global spinal surgery
market. For more information, visit www.K2M.com and connect with us
on Facebook, Twitter, Instagram, LinkedIn and YouTube.
Forward-Looking Statements
This press release contains forward-looking statements that
reflect current views with respect to, among other things,
operations and financial performance. Forward-looking
statements include all statements that are not historical facts
such as our statements about our expected financial results and
guidance and our expectations for future business prospects.
In some cases, you can identify these forward-looking statements by
the use of words such as, "outlook," "guidance," "believes,"
"expects," "potential," "continues," "may," "will," "should,"
"could," "seeks," "predicts," "intends," "plans," "estimates,"
"anticipates" or the negative version of these words or other
comparable words. Such forward-looking statements are subject
to various risks and uncertainties including, among other things:
our ability to achieve or sustain profitability in the future; our
ability to demonstrate to spine surgeons the merits of our products
and retain their use of our products; pricing pressures and our
ability to compete effectively generally in our industry;
collaboration and consolidation in hospital purchasing; inadequate
coverage and reimbursement for our products from third-party
payers; lack of long-term clinical data supporting the safety and
efficacy of our products; dependence on a limited number of
third-party suppliers; our ability to maintain and expand our
network of direct sales employees, independent sales agencies and
international distributors and their level of sales or distribution
activity with respect to our products; proliferation of
physician-owned distributorships in the industry; decline in the
sale of certain key products; loss of key personnel; our ability to
enhance our product offerings through research and development; our
ability to manage expected growth; our ability to successfully
acquire or invest in new or complementary businesses, products or
technologies; our ability to educate surgeons on the safe and
appropriate use of our products; costs associated with high levels
of inventory; impairment of our goodwill and intangible assets;
disruptions to our corporate headquarters and operations facilities
or critical information technology systems, distributors or surgeon
users; our ability to ship a sufficient number of our products to
meet demand; our ability to strengthen our brand; fluctuations in
insurance cost and availability; our ability to comply with
extensive governmental regulation within the United States and
foreign jurisdictions; our ability to maintain or obtain
regulatory approvals and clearances within the United States and
foreign jurisdictions; voluntary corrective actions by us or our
distribution or other business partners or agency enforcement
actions; recalls or serious safety issues with our products;
enforcement actions by regulatory agencies for improper marketing
or promotion; misuse or off-label use of our products; delays or
failures in clinical trials and results of clinical trials; legal
restrictions on our procurement, use, processing, manufacturing or
distribution of allograft bone tissue; negative publicity
concerning methods of tissue recovery and screening of donor
tissue; costs and liabilities relating to environmental laws and
regulations; our failure or the failure of our agents to comply
with fraud and abuse laws; U.S. legislative or Food and Drug
Administration regulatory reforms; adverse effects of medical
device tax provisions; potential tax changes in jurisdictions in
which we conduct business; our ability to generate significant
sales; potential fluctuations in sales volumes and our results of
operations over the course of the year; uncertainty in future
capital needs and availability of capital to meet our needs; our
level of indebtedness and the availability of borrowings under our
credit facility; restrictive covenants and the impact of other
provisions in the indenture governing our convertible senior
notes and our credit facility; continuing worldwide economic
instability; our ability to protect our intellectual property
rights; patent litigation and product liability lawsuits; damages
relating to trade secrets or non-competition or non-solicitation
agreements; risks associated with operating internationally;
fluctuations in foreign currency exchange rates; our ability to
comply with the Foreign Corrupt Practices Act and similar laws; our
ability to implement and maintain effective internal control over
financial reporting; potential volatility in our stock price; our
lack of current plans to pay cash dividends; increased costs and
additional regulations and requirements as a result of no longer
qualifying as an emerging growth company as of December 31, 2017;
potential dilution by the future issuances of additional common
stock in connection with our incentive plans, acquisitions or
otherwise; anti-takeover provisions in our organizational documents
and our ability to issue preferred stock without shareholder
approval; potential limits on our ability to use our net operating
loss carryforwards; and other risks and uncertainties, including
those described under the section entitled "Risk Factors" in our
most recent Annual Report on Form 10-K filed with the SEC and our
Quarterly Report filed with the SEC on November 1, 2017, as such
factors may be updated from time to time in our periodic filings
with the SEC, which are accessible on the SEC's website
at www.sec.gov. Accordingly, there are or will be
important factors that could cause actual outcomes or results to
differ materially from those indicated in these statements.
These factors should not be construed as exhaustive and should be
read in conjunction with the other cautionary statements that are
included in this release and our filings with the SEC.
We operate in a very competitive and challenging
environment. New risks and uncertainties emerge from time to
time, and it is not possible for us to predict all risks and
uncertainties that could have an impact on the forward-looking
statements contained in this release. We cannot assure you
that the results, events and circumstances reflected in the
forward-looking statements will be achieved or occur, and actual
results, events or circumstances could differ materially from those
described in the forward-looking statements.
The forward-looking statements made in this press release relate
only to events as of the date on which the statements are
made. We undertake no obligation to publicly update or review
any forward-looking statement, whether as a result of new
information, future developments or otherwise, except as required
by law. We may not actually achieve the plans, intentions or
expectations disclosed in our forward-looking statements and you
should not place undue reliance on our forward-looking statements.
Unless specifically stated otherwise, our forward-looking
statements do not reflect the potential impact of any future
acquisitions, mergers, dispositions, joint ventures, investments or
other strategic transactions we may make.
Investor Contact:
Westwicke Partners on behalf of K2M Group Holdings, Inc.
Mike Piccinino, CFA, 443-213-0500
K2M@westwicke.com
K2M GROUP HOLDINGS, INC. (NASDAQ:KTWO)
Historical Stock Chart
From Aug 2024 to Sep 2024
K2M GROUP HOLDINGS, INC. (NASDAQ:KTWO)
Historical Stock Chart
From Sep 2023 to Sep 2024